Full-Time

Senior Scientist

Translational Research

Confirmed live in the last 24 hours

Absci

Absci

51-200 employees

Biotech company specializing in protein production

Compensation Overview

$127k - $165k/yr

+ Equity Package

Senior

No H1B Sponsorship

Vancouver, WA, USA

Legal authorization to work in the United States is required.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Life Sciences (Pharmacology, Biochemistry, Biology) with 5+ years of relevant experience in drug discovery or clinical development
  • Proven experience in translational research and/or early clinical trials, preferably with biologics, including interactions with health authorities (e.g., IND/CTA filings)
  • Documented industry experience in translating early research into preclinical and clinical development activities, including coordination with CROs and consultants
  • Demonstrated track record in drug discovery with expertise in in vitro and in vivo pharmacology, biomarker identification and validation, ADME/PK, and toxicology
  • Demonstrated alignment with Absci's core values, including a passion for innovation, belief and desire in working as one team to achieve our mission, and a commitment to excellence in all endeavors.
Responsibilities
  • Provide key translational insights to support drug target validation and selection, enhancing Absci’s drug creation pipeline
  • Serve as the primary contact for the design and implementation of translational strategies based on a robust disease biology understanding
  • Generate and interpret pharmacological efficacy, pharmacokinetic, safety, and toxicological data in collaboration with disease biology experts to advance programs
  • Design and execute translational and toxicological studies, ensuring rigorous scientific standards
  • Oversee preclinical CRO activities, including project design, timelines, budgets, and deliverables
  • Contribute to the development of early clinical strategies by leveraging biomarker insights
  • Work closely with project team members across disciplines to rapidly advance projects into clinical development
  • Build and maintain strong relationships with key external stakeholders, including investigators, Key Opinion Leaders, and health authorities
  • Contribute to scientific publications and patents, and present results at scientific conferences and meetings.
Desired Qualifications
  • Candidates who will dive into our creative company culture that’s collaborative, multidisciplinary, and committed to a big vision for positive impact
  • Original thinkers, creative scientists, and data-devoted gurus
  • Successful candidates will be excited to work in a dynamic environment and contribute as a key member of a project team.

AbSci focuses on improving protein expression and biomanufacturing in the biotech industry. Its main product is an advanced protein expression platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system, allowing for better control over protein production rates. This results in higher quality and more efficient drug manufacturing. A key feature of AbSci's offerings is SoluPure, a method that simplifies protein purification without chromatography, speeding up the production process and reducing costs. Unlike traditional methods that rely on mammalian cells, AbSci's technology can generate cell lines that produce active proteins in just three months. The company partners with pharmaceutical and biotech firms to provide these efficient solutions, aiming to transform drug discovery and manufacturing practices. AbSci's goal is to challenge conventional methods and create better tools for producing life-saving biologics.

Company Size

51-200

Company Stage

IPO

Headquarters

Vancouver, Washington

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Absci's partnerships with AMD and Owkin enhance AI-driven drug discovery capabilities.
  • Generative AI collaborations with MSK and Twist Bioscience accelerate novel therapeutic development.
  • Increased adoption of AI and synthetic biology boosts Absci's innovative drug designs.

What critics are saying

  • Growing competition in AI-driven drug discovery may impact Absci's market share.
  • Dependence on partnerships could pose risks if collaborations don't yield results.
  • Rapid tech advancements could render Absci's current technologies obsolete.

What makes Absci unique

  • Absci uses AI and synthetic biology for novel protein-based drug discovery.
  • Their SoluPure method simplifies protein purification, reducing production time and costs.
  • Absci's high-throughput workflow generates active protein products in just three months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
GlobeNewswire
Jan 10th, 2025
Absci And Owkin Synergize Leading Techbio Platforms To Advance Generative Ai Drug Discovery

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids

Aitech365
Jan 9th, 2025
Absci & AMD Announce Collaboration to Boost AI Drug Discovery

Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT.

SiliconANGLE
Jan 8th, 2025
AMD invests $20M in Absci's AI drug discovery

AMD has invested $20 million in Absci Corp., an AI-driven drug discovery company. The partnership will see Absci shift some workloads to AMD's Instinct AI processors, enhancing its research capabilities. Absci will use the investment to improve its AI models and collaborate with AMD on developing new hardware and software for healthcare, focusing on drug discovery advancements.

GlobeNewswire
Jan 8th, 2025
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) - Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models.

247 Market News
Jan 8th, 2025
"Top Stocks Traders Are Buying Today: SANA, SYTA, CURR, EONR, and ABSI - Hot Picks Driving the Market"

Absci (NASDAQ: ABSI), a leader in AI-driven drug discovery, secured a $20 million strategic investment from Advanced Micro Devices (AMD).